) in peripheral immune organs, which resulted in attenuated EAE. However, the proportions of T helper type 1 (Th1) and Th17 cells in spleen and lymph nodes and the levels of pro-inflammatory cytokines and IgG in serum also increased after transfer of VD 3 -DCs. We conclude that transfer of VD 3 -DCs suppressed EAE by increasing proportions of regulatory T cells, CD4 + IL-10 + T cells and regulatory B cells in spleen and reducing infiltration of Th1 and Th17 cells into spinal cord, which suggests a possible immunotherapy method using VD 3 -DCs in MS.
Summary
Dendritic cells (DCs), a bridge for innate and adaptive immune responses, play a key role in the development of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE), an animal model for MS. Administration of tolerogenic DCs has been used as an immunotherapy in autoimmune diseases. Deficiency of vitamin D is an environmental risk factor of MS. In this study, we induced tolerogenic DCs by 1,25-dihydroxyvitamin D 3 and transferred the tolerogenic DCs (VD 3 -DCs) into EAE mice by adoptive transfer. We found that VD 3 ) in peripheral immune organs, which resulted in attenuated EAE. However, the proportions of T helper type 1 (Th1) and Th17 cells in spleen and lymph nodes and the levels of pro-inflammatory cytokines and IgG in serum also increased after transfer of VD 3 -DCs. We conclude that transfer of VD 3 -DCs suppressed EAE by increasing proportions of regulatory T cells, CD4
Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating disease in the central nervous system (CNS), which leads to a very high level of neurological disability. 1 However, lack of efficient specific immunotherapy in MS has been a serious problem.
Dendritic cells (DCs), a bridge between innate and adaptive immune responses, are a type of antigen-presenting cell that participate in the initiation and development of MS and experimental autoimmune encephalomyelitis (EAE), an animal model of MS. 2 Besides inducing an immune response, DCs can also generate immunological tolerance. 3 DCs play an essential role in protecting against a severe autoimmune response under steady conditions and DCdepleted mice developed spontaneous severe autoimmune disease. 4 Tolerogenic DCs are a special type of DC that contribute to tolerance rather than immunity. Tolerogenic DCs suppress immune responses by expressing co-inhibitory molecules, secreting anti-inflammatory cytokines, 
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inducing T-cell anergy and generating regulatory T (Treg) cells. 5 The Treg cell is a regulatory cell that has the ability to maintain peripheral tolerance and prevent autoimmune diseases. It can reduce the functions of some pathogenic cells by molecule secretion or direct contact. 6 T helper type 1 (Th1) cells, a subset of pathogenic T cells, play an important role in the pathogenesis of MS and EAE. 7 Adoptive transfer of myelin-specific Th1 cells into mice induced severe EAE. 7 T helper type 17 (Th17) cells are also a subset of pathogenic T cells that contribute to the development of MS and EAE. Th17 cells exist in the CNS lesions of patients with MS, 7 and increased Th17 cells were found in the peripheral blood of patients with MS during acute relapse. 2 During the process of activation of Th1 and Th17 cells, DCs play a crucial role. 8 In peripheral lymphoid organs, DCs combine with T cells by their surface molecules and provide co-stimulatory signals to promote the polarization of Th1 cells. Then T cells are activated by DCs and other antigen-presenting cells, again after crossing the blood-brain barrier and participate in mediating demyelination in the CNS. 9 On the basis of the immunosuppressive function of DCs, adoptive transfer of tolerogenic DCs could be applied in the therapy of various types of autoimmune diseases. It has been reported that the level of vitamin D in patients with MS is lower than in healthy control individuals and deficiency of vitamin D is an environmental risk factor for MS. 1 Other studies have demonstrated that vitamin D 3 -induced DCs (VD 3 -DCs) showed a similar characterization to tolerogenic DCs and have the ability to ameliorate EAE in mice. These studies reported that VD 3 -DCs inhibited the severity of EAE through reducing the proportion of CD11c + DCs, and increasing the proportion of Treg cells and the secretion of interleukin-10 (IL-10). [10] [11] [12] The effect of VD 3 -DCs on pathogenic T cells and humoral immunity in MS and EAE is still unknown.
We cultured DCs with 1,25-dihydroxyvitamin D 3 (1,25 (OH) 2 D 3 ) and transferred VD 3 -DCs in EAE to explore their therapeutic effect and therapeutic mechanism. Our study demonstrated that VD 3 -DCs had the ability to alleviate EAE, although the inflammatory response in secondary immune organs and the blood became more severe after the transfer of VD 3 -DCs. According to the results, we infer that VD 3 -DCs alleviated EAE by enhancing the proportions of Treg cells, CD4
+ IL-10 + T cells and regulatory B (Breg) cells, and by inhibiting the infiltration of Th1 and Th17 cells from peripheral tissues into the spinal cord.
Materials and methods

Induction of EAE and assessment of clinical signs
Female C57BL/6 mice, 6-8 weeks of age and weighing 18-20 g (Vital River Laboratory Animal Technology Co.
Ltd., Beijing, China), were used for the induction of EAE in the study. EAE was induced by subcutaneous injection of myelin oligodendrocyte glycoprotein 35-55 (MOG 
Generation and transfer of DCs and VD 3 -DCs
On days 2, 5 and 8 p.i., C57BL/6 mice were killed and femurs and tibiae were separated from muscle tissues. The bones were cut and bone marrow cells were extracted from them in RPMI-1640 complete medium (Gibco, Waltham, MA). After lysis of red blood cells, bone marrow cells were cultured in RPMI-1640 complete medium (Gibco) supplemented with fetal bovine serum (10%; Biological Industries, Kibbutz Beit-Haemek, Israel), penicillin and streptomycin (1%; Hyclone, Logan, UT), granulocyte-macrophage colony-stimulating factor (10 ng/ml; eBioscience, San Diego, CA) and IL-4 (10 ng/ml; PeproTech, Rocky Hill, NJ). The medium for preparation of tolerogenic DCs was added with 1,25(OH) 2 On day 20 p.i. (the peak of disease), EAE mice were killed and cells were isolated from spleens and lymph nodes. After being stimulated with leucocyte cocktail activation for 8 hr, cells were stained using the following antibodies: CD3-FITC, CD4-Peridinin chlorophyll protein-Cy5.5, IL-17A-Bv421, interferon-c (IFN-c) -APC, IL-10-PE, CD25-PE-CF594 and Foxp3-PE (BD Biosciences). For extracellular molecules like CD3, CD4 and CD25, cells were incubated with antibodies for 30 min at 4°. For intracellular molecules like IL-17A, IFN-c and IL-10, cells were fixed with 2% paraformaldehyde (Solarbio, Beijing, China) for 20 min at room temperature. After being permeabilized with 0Á5% saponin (Sigma Aldrich), cells were incubated with antibodies for 30 min at 4°. For endonuclear molecules like FoxP3, cells were stained according to the instructions provided by the manufacturer (BD Biosciences). Flow cytometric analysis was performed by using FLOWJO 7.6.1 (Treestar).
Regulatory B cells were isolated from spleen and lymph nodes of EAE mice on day 20 p.i. and then stained with the following antibodies (CD3-FITC, CD19-PE-Cy7, CD1d-BV510 and CD5-APC; BD Biosciences) for 30 min at 4°. Data analysis for flow cytometry was performed using FLOWJO 7.6.1 (Treestar).
Histological evaluation
On day 20 p.i., spinal cords of mice were taken out after being perfused by intracardiac infusion with 4% paraformaldehyde. The spinal cords were fixed in 4% buffered formalin, embedded in paraffin wax, cut into sections (6 lm) and stained with haematoxylin & eosin for pathological examination.
Immunofluorescence staining
On day 20 p.i., the mice were anaesthetized and perfused by intracardiac infusion with 4% paraformaldehyde. The spinal cords were sampled and fixed in 4% paraformaldehyde for 24 hr at 4°, and then dehydrated using sucrose solution, embedded in optimal cutting temperature compound (Sakura, Tokyo, Japan) and sliced into samples. Spinal cord samples were incubated with proteinase K (Merck, Darmstadt, Germany) for 10 min at 37°and subsequently incubated with reagent comprising 89Á4% PBS, 10% goat serum (Bioss, Beijing, China) and 0Á6% Trition (Sigma Aldrich) for 1 hr at 4°. The samples were stained with primary antibodies to CD4 (1 : 150), T-bet (1 : 200) and ROR-ct (1 : 200) (Abcam, Cambridge, UK) for 12 hr at 4°, followed by secondary antibodies to goat anti-rat (AF-647), goat anti-mouse (AF-488) and goat anti-rabbit (AF-488) (Abcam) separately for 1 hr at room temperature. After being stained with 4 0 ,6-diamidino-2-phenylindole (Boster, Hubei, China), immunofluorescence analysis was performed on a fluorescence microscope (Olympus BX51, Japan).
Cytokine cytometric bead array
On day 20 p.i., EAE mice were killed and peripheral blood was collected. Serum was obtained after centrifugation at 2092 g for 10 min. The levels of IL-2, IL-4, IL-6, IL-10, IL-17A, tumour necrosis factor (TNF) and IFN-c in serum were measured by cytometric bead array (CBA) kits (BD Bioscience) according to the manufacturer's instructions. Determinations were performed twice and results are expressed as pg/ml.
Detection of IgG by ELISA
The level of IgG in serum was detected with ELISA kits (GenWay, San Diego, CA). The serum was prepared in a dilution of 1/200 000 and the assay was performed according to the manufacturer's instructions. Determinations were performed in triplicate and plates were read on a microplate reader (Bio-Rad, Hercules, CA).
Statistical analysis
All experiments were replicated three times. Data were expressed as the mean AE standard deviation (SD) values. The flow cytometry data were analysed using FLOWJO 7.6.1 (Treestar) and graphed using GRAPHPAD PRISM version 5.0 (GraphPad Software Inc., San Diego, CA). Other statistical analyses were performed using GRAPHPAD PRISM version 5.0 (GraphPad Software Inc.) and SPSS 21.0 (IBM Deutschland, Ehningen, Germany). One-way analysis of variance followed by Bonferroni's post-test was used to compare values among three groups and Student's t-test was used to compare values between two groups. All tests were two-tailed, with the level of significance set to P < 0Á05.
Results
1,25(OH) 2 D 3 induces tolerogenic DCs efficiently
Bone-marrow-derived DCs from EAE mice were incubated with 1,25(OH) 2 D 3 for 8 days and the phenotype was identified. The results showed that 1,25(OH) 2 D 3 down-regulated the expression of MHC-II and CD86 on DCs (P < 0Á001). However, no significant difference in the expression of CD83 and CD80 between VD 3 -DCs and DCs was observed (P > 0Á05) (Fig. 1a) .
VD 3 -DCs retained immature phenotype after being stimulated with lipopolysaccharide (Fig. 1b) . VD 3 -DCs still had lower expression of MHC-II (P < 0Á001) and CD86 (P < 0Á01), and higher expression of CD80 (P < 0Á05) than DCs. But there was no significant difference in the expression of CD83 between the two groups (P > 0Á05). Our results implied that incubation with 1,25 (OH) 2 D 3 led to generation of tolerogenic DCs.
VD 3 -DCs ameliorates EAE
To determine the effect of VD 3 -DCs and DCs on EAE, VD 3 -DCs and DCs loaded with MOG peptide were transferred to EAE mice by the caudal vein on days 10, 13 and 16 post-immunization. Both VD 3 -DCs and DCs treated EAE mice showed reduced clinical scores (mean clinical score of each group) when compared with the controls (controls: 3 AE 1Á05, DCs group: 1Á6 AE 0Á57, VD 3 -DCs group: 0Á9 AE 0Á57; VD 3 -DCs group versus the controls, P < 0Á001; DCs group versus the controls, P < 0Á05) (Fig. 2a) . Injection of VD 3 -DCs significantly postponed the onset of EAE compared with administration to the DCs group and the controls (controls: 12Á5 AE 0Á3 days, VD 3 -DCs group: 14Á6 AE 0Á4 days; P < 0Á001) (Fig. 2b) , but when DCs group (12Á3 AE 0Á4 days) was compared with the controls, the difference was not significant (P > 0Á05) (Fig. 2b) .
Histological evaluation showed consistent results with the clinical score. The extent of inflammatory cell infiltration decreased in the VD 3 -DCs group and DCs group (Fig. 2c) .
VD 3 -DCs inhibit the infiltration of Th1 and Th17 cells into spinal cord
To explore the mechanism behind the therapeutic effect of VD 3 -DCs on EAE, we measured the numbers of infiltrations of Th1 and Th17 cells in the spinal cords of EAE. As presented in Fig. 3 with the DCs group (26Á1 AE 6Á2; P < 0Á001) and the controls (52Á1 AE 20Á1; P < 0Á001). When comparing the DCs group with the controls, the difference also reached statistical significance (P < 0Á001). Similar profiles of Th17 cell infiltration in the spinal cord were found in these groups. The numbers of Th17 cells were also decreased in the VD 3 -DCs group (17Á3 AE 4Á5) compared with the DCs group (26Á3 AE 6Á1; P < 0Á001) and the controls (46Á3 AE 15Á3; P < 0Á001). Our results suggested that administration of VD 3 -DCs ameliorated EAE by reducing the infiltration of Th1 and Th17 cells in the spinal cords. To investigate the mechanism of VD 3 -DCs therapeutic effect further, we analysed the proportion of Treg, CD4 + IL-10 + T, Th1 and Th17 cells in the spleen and lymph nodes. In the spleen, the proportion of Treg (CD4 + CD25 + Foxp3 + ) cells in CD4 + T cells was increased in the VD 3 -DCs group compared with the controls (P < 0Á05) (Fig. 4a) . But the proportion of Treg cells showed no significant difference between the VD 3 -DCs group and the DC group nor between the DC group and the controls (P > 0Á1) (Fig. 4a) . In lymph nodes, the proportion of Treg cells was elevated in the VD 3 -DCs group compared with the DCs group (P < 0Á05) (Fig. 4b ) and the controls (P < 0Á01) (Fig. 4b) , but there was no significant difference between the DCs group and the controls (P > 0Á05) (Fig. 4b) . Higher numbers of CD4 + IL-10 + T cells in the spleen and lymph nodes were found in the VD 3 -DCs group than in the controls (P < 0Á05) (Fig. 4c,  d ). However, there was no significant difference regarding the numbers of CD4 + IL-10 + T cells between the VD 3 -DCs group versus the DCs group, and the DCs group versus the controls (P > 0Á05) (Fig. 4c,d ). In addition, there was an unexpected result that VD 3 -DCs also increased the proportion of Th1 (CD4 + IFN-c + ) and Th17 (CD4 + IL-17A + ) cells in spleen, which can promote the development of EAE. Our results showed that proportions of Th1 and Th17 cells in the spleen were up-regulated in the VD 3 -DCs group compared with the controls (P < 0Á05) (Fig. 4e,g ). Similar profiles of the proportions of Th1 and Th17 cells were found in lymph nodes when comparing the VD 3 -DCs group with the controls (P < 0Á05) (Fig. 4f,h) . The difference of the proportion of Th17 cells in lymph nodes also showed a statistical significance between the DCs group and the controls (P < 0Á05) (Fig. 4h) .
VD 3 -DCs increase the levels of IL-17A and TNF
To investigate the effect of VD 3 -DCs on cytokines in serum, the levels of IL-2, IL-4, IL-6, IL-10, IL-17A, TNF and IFN-c were measured using CBA kits. The level of TNF increased in both the VD 3 -DCs and the DCs groups compared with the controls (P < 0Á05) (Fig. 5a) . The level of IL-17A increased in the VD 3 -DCs group compared with other two groups (P < 0Á05) (Fig. 5b) . The level of IFN-c decreased in the DCs group (P < 0Á05) (Fig. 5c) . Differences in the levels of IL-6 ( Fig. 5d ), IL-10 ( Fig. 5e ) and IL-4 ( Fig. 5f ) among the three groups were not significant (P > 0Á05) and the level of IL-2 could not be detected (data not show).
VD 3 -DCs increase the proportions of Breg cells in spleen
To investigate whether VD 3 -DCs can regulate the humoral immunity in EAE, we analysed the proportion of Breg cells in the spleen and lymph nodes. In the spleen, the proportion of Breg cells (CD19 + CD5 + CD1d + ) increased significantly in the VD 3 -DCs group compared with the DCs group (P < 0Á01) (Fig. 6a ) and the controls (P < 0Á05) (Fig. 6a) . The proportion of Breg cells in the DCs group was slightly lower than in the controls, but the difference between these two groups was not significant (P > 0Á05) (Fig. 6a) . In lymph nodes, the proportion of Breg cells increased slightly in the VD 3 -DCs group and DC group compared with the controls, but there were no significant differences between any two groups (P > 0Á05) (Fig. 6b) .
VD 3 -DCs increase the level of IgG in serum
To determine whether VD 3 -DCs can influence the humoral immunity, we detected the level of IgG in serum by ELISA kits. As shown in Fig. 6(c) , the level of IgG increased in the VD 3 -DCs group compared with the controls (P < 0Á05). But there were no significant differences between the controls and the DCs group nor between the DCs group and the VD 3 -DCs group (P > 0Á05).
Discussion
Multiple sclerosis is a serious disease and has been researched for years, but there is still a lack of efficient specific immunotherapy. 1 In this study, we found that 1,25(OH) 2 D 3 -induced tolerogenic DCs have the ability to alleviate EAE by increasing proportions of Treg, The DCs play a crucial role in the pathogenesis of MS and EAE. They take up and process antigens loaded on the MHC, present antigens to T cells and then activate T cells through expression of co-stimulatory molecules such as CD86 and CD83. 9 Tolerogenic DCs, which can result in T-cell unresponsiveness, express lower levels of MHC-II and co-stimulatory molecules than normal DCs. 9, 13, 14 Our results showed that 1,25(OH) 2 D 3 down-regulated the expression of MHC-II, CD86 and CD83 on DCs, and the expression of these surface molecules on VD 3 -DCs was still lower than DCs after stimulation with lipopolysaccharide, which is a pro-inflammatory mediator. 15 These results indicate that VD 3 -DCs are a type of steady tolerogenic DC.
In this study, both VD 3 -DCs and normal DCs inhibited EAE. The normal DCs that transferred to EAE in our study were not stimulated by lipopolysaccharide, so they were still immature and their surface markers like MHC-II and CD86 remained at a low level. The immature phenotype of normal DCs may be the reason why they can also have curative effects.
The Treg cells are a subset of CD4 + T cells and have the ability to maintain immune tolerance. 12, 16 A variety of treatments in MS/EAE are reported through up-regulating the number of Treg cells. [17] [18] [19] In addition to Treg cells, CD4
+ IL-10 + T cells are also a subset of CD4 + T cells, which regulate the immune response by secretion of IL-10 and transforming growth factor-b. In this study, we found that transfer of VD 3 One-way analysis of variance followed by Bonferroni's post-test was used. ns, no significant difference; *P < 0Á05; **P < 0Á01 (n = 6). Immunoglobulins, key effector molecules of the humoral adaptive immune system, are the main secretory products of plasma cells. They bind antigen by their variable regions and present to Fc receptors and C-type lectin receptors, which can be expressed on DCs and subsequently mediate immune responses. 24, 25 Our results found enhanced inflammatory responses and inflammatory cytokines in the peripheral immune organs and blood in the EAE model after adoptive transfer of VD 3 -DCs and DCs. However, the increased inflammatory responses in the periphery seem to contravene the decreased Th1 and Th17 cell infiltration into the CNS and alleviate clinical symptoms in the VD 3 -DCs and DCs groups. In the development of MS and EAE, pathogenic T cells go through three main processes: activation by antigen-presenting cells in the periphery, crossing the blood-brain barrier and re-stimulation by antigen-presenting cells, again in the CNS. 26 Hence, we supposed that VD 3 -DCs alleviated EAE by inhibiting the migration of Th1 and Th17 cells from peripheral organs into the CNS rather than reducing the numbers of Th1 and Th17 cells in the peripheral immune organs. 
(c) Figure 6 . Dendritic cells treated with 1,25-dihydroxyvitamin D 3 (VD 3 -DCs) increase the proportion of Breg cells in spleen and the secretion of IgG in serum. On day 20 p.i., experimental autoimmune encephalomyelitis (EAE) mice (induced by female C57BL/6 mice) were killed, cells were isolated from spleen and lymph nodes of mice and serum was obtained after centrifugation of blood at 2092 g for 10 min. Cells were analysed using flow cytometry as described in the Materials and methods and the levels of IgG were evaluated using ELISA kits according to the manufacturer's instructions. In spleen (a), the proportion of Breg cells increases in the VD 3 -DCs group whereas the proportion of it decreases in the DCs group. In lymph nodes (b), the proportions of Breg cells have a slight increase in both the VD 3 -DCs group and the DCs group. The level of IgG increases in the VD 3 -DCs group significantly. But the differences between the DCs group and the controls as well as the VD 3 -DCs group and the DCs group are not significant (c). Experiments were replicated three times and data are shown as the mean AE SD. One-way analysis of variance followed by Bonferroni's post-test was used. ns, no significant difference; *P < 0Á05; **P < 0Á01 (n = 6). Lymphocyte function associated antigen-1 (LFA-1) and its adhesive ligands, such as intercellular adhesion molecule-1 (ICAM-1), are crucial in lymphocyte trafficking and adaptive immune responses. 27 After the stimulation of antigen presented by MHC, T-cell receptors can cluster LFA-1 in the membrane of T cells, induce their conformational changes and thereby increase the binding affinity of LFA-1 through activating 'inside-out' signalling. 28 The nuclear factor jB (NF-jB) binding site, located upstream of the ICAM-1 transcription initiation site, is particularly important for the transcription of ICAM-1. 29 1,25(OH) 2 D 3 can reduce nuclear translocation of NF-jB and decrease the level of NF-jB in the nucleus. 30, 31 Consequently, 1,25(OH) 2 D 3 may reduce the combination of NF-jB with its binding site and down-regulate the expression of ICAM-1 on DCs.
In this study, we found that treatment with 1,25 (OH) 2 D 3 significantly down-regulated the expression of MHC-II on DCs, the decrease of MHC-II may reduce the activation of 'inside-out' signalling in T cells and downregulate the affinity of LFA-1 with ICAM-1.
28 VD 3 -DCs may reduce the combination of ICAM-1 and LFA-1 through the low expression of NF-jB and MHC-II. [29] [30] [31] These may be the mechanisms by which VD 3 -DCs inhibit the migration of pathogenic T cells such as Th1 and Th17 cells.
Although EAE initiates mainly by T cells, humoral immunity also plays a crucial role in disease pathogenesis. 32, 33 Breg cells are a specific subset of B cells that negatively regulate immune responses and support immunological tolerance. They have the ability to suppress MS activity through inhibiting Th1 and Th17 differentiation or maintaining Treg cells. 34 In our study, the percentage of Breg cells in CD19 + B cells in spleen increased after transferring VD 3 -DCs. The increased Breg cells can suppress immune responses thorugh maintenance of Treg cells and prohibition of pathogenic lymphocyte expansion .35 In conclusion, 1,25(OH) 2 D 3 can induce DCs to tolerogenic DCs, which inhibited EAE. Treatment with VD 3 -DCs enhanced the proportions of Treg, CD4
+ IL-10 + T and Breg cells and inhibited infiltration of Th1 and Th17 cells into spinal cord. But VD 3 -DCs also increased proportions of Th1 and Th17 cells in spleen and lymph nodes and the levels of some pro-inflammatory cytokines and IgG in serum. According to the results, we infer that VD 3 -DCs alleviated EAE by inhibiting the migration of Th1 and Th17 cells from peripheral organs to the CNS rather than inhibiting the inflammatory response in the periphery. Our findings may provide a rationale for applying a possible immunotherapeutic method in EAE, which may be a highly promising method for treatment of autoimmune disease in humans. However, the exact mechanisms of VD 3 -DC in the treatment of EAE still merit further investigation.
